“They are interested in pharmacogenetic purposes to do case control studies of
adverse drug reactions,” said John Novembre, a co-author of the study published
in Nature. …
the public doesn’t trust pharma to share adverse info on their meds, further undermining that faith–and hurting
pharma’s rep. …
Eli Lilly will face a class-action suit over Zyprexa, now that a federal judge
has certified a group of insurance companies, pension funds, and unions that
want the drugmaker to repay them for the billions they spent on the
controversial antipsychotic drug. …
Until now, all the evidence for long-term maintenance of efficacy of Sativex has
come from long-term open-label exposurei. The results reported today confirm in
the context of a placebo-controlled double-blind study that efficacy is indeed
maintained in long-term use. …